Rhythm Pharmaceuticals share price logo

Rhythm Pharmaceuticals

NASDAQ: RYTM

Mid Cap

$98.66

+0.35

(+0.36%)

as on

Rhythm Pharmaceuticals Stock Performance

as on September 26, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $96.35
    $99.44
    downward going graph

    2.34%

    Downside

    0.79%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $74.50
    $122.20
    downward going graph

    24.49%

    Downside

    23.86%

    Upside

    downward going graph

Rhythm Pharmaceuticals share price movements today

Previous Close
$98.31
Open
$98.96
Volume
1.3M
Market Cap
$6.7B
Day's Low - High
$96.35 - $99.44
52 Week Low - High
$74.50 - $122.20

Rhythm Pharmaceuticals Historical Returns

1 Month Return
-11.81 %
3 Month Return
-10.18 %
1 Year Return
-0.5 %
3 Year Return
+ 315.06 %
5 Year Return
+ 659.51 %

Rhythm Pharmaceuticals Stock Fundamentals & Key Indicators

Check Rhythm Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$6.7B

EPS (TTM)

-3.11

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-31.61

Industry PE ratio

-12.76

PEG Ratio

7.907609397195108

EBITDA

-184.7M

Revenue (TTM)

239.9M

Profit Margin

89.00%

Return On Equity TTM

-80.48%

Rhythm Pharmaceuticals Stock Valuation

Track how Rhythm Pharmaceuticals P/E has moved over time to understand its valuation trends.

Rhythm Pharmaceuticals in the last 5 years

  • Overview

  • Trends

Lowest (-34.42x)

December 31, 2025

Today (-34.42x)

December 31, 2025

Industry (-12.76x)

December 31, 2025

Highest (-7.11x)

December 31, 2021

LowHigh

Today’s Price to Earnings Ratio: -34.42x

Rhythm Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Rhythm Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Rhythm Pharmaceuticals image
Rhythm Pharmaceuticals
StrongBuy$6.7B659.51%-31.6189.00%0.00%
Moderna image
Moderna
Neutral$77.8B-53.76%-24.41-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$132.4B186.58%30.1686.04%0.00%
Regeneron image
Regeneron
Buy$82.8B23.34%19.0184.86%0.46%

Stock Returns calculator for Rhythm Pharmaceuticals Stock including INR - Dollar returns

The Rhythm Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Rhythm Pharmaceuticals investment value today

Current value as on today

₹1,07,392

Returns

₹7,392

(+7.39%)

Returns from Rhythm Pharmaceuticals Stock

-₹504 (-0.50%)

Dollar Impact

₹7,896 (+7.9%)

Analyst Recommendation on Rhythm Pharmaceuticals Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.88888888888889% of analysts recommend a 'BUY' rating for Rhythm Pharmaceuticals. Average target price of $138.59

Rhythm Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Rhythm Pharmaceuticals.

What analysts predicted

28.81%UPSIDE

Target Price

$138.59

Current Price

$98.66

Analyzed by

9 Analysts

High

$160

Target

$138.59

Low

$120

Rhythm Pharmaceuticals target price $138.59, a slight upside of 28.81% compared to current price of $98.66. According to 9 analysts rating.

Indian Investors' Interest in Rhythm Pharmaceuticals Stock

Search interest for Rhythm Pharmaceuticals Stock has decreased by -29% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-29% versus previous 30 day period

Rhythm Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
25
29
33
41
32
48
51
57
60
71
Gross Profit
23
26
29
38
29
42
45
52
52
62
Operating Income
-139
-40
-43
-41
-47
-45
-52
-47
-52
-48
EBITDA
-135
-26
-38
-37
-43
-40
-47
-42
-50
-44
Interest Expense
4
4
5
5
5
5
4
4
4
4
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-141
-31
-43
-43
-49
-46
-52
-47
-55
-48
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-141
-32
-43
-43
-49
-46
-52
-47
-55
-49
Net Profit Margin
89.19%
89.87%
88.49%
90.95%
88.85%
88.57%
89.28%
91.61%
88.09%
87.47%

Rhythm Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
3
23
77
130
189
Gross Profit
0
0
0
0
2
21
68
116
170
Operating Income
-32
-78
-146
-136
-170
-179
-184
-265
-192
EBITDA
-32
-77
-145
-135
-68
-174
-168
-238
-174
Interest Expense
-
-
-
-
-
5
13
20
20
Depreciation
0
0
0
0
1
1
1
1
1
Income Before Tax
-33
-74
-140
-133
-69
-181
-184
-260
-196
Income Tax Expense
-
-
-
-
-
-
0
0
0
Net Income
-33
-74
-134
-130
-69
-181
-184
-260
-196
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
81.01%
90.98%
87.99%
89.73%
89.73%

Rhythm Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-141
-32
-43
-43
-49
-46
-52
-47
-55
-104
Operating Cash Flow
-40
-29
-25
-18
-40
-23
-26
-25
-44
-53
Investing Cash Flow
30
-8
-90
21
24
54
-246
30
57
71
Financing Cash Flow
4
146
2
38
32
0
189
-2
-5
-6
Change in Cash
-6
108
-114
41
16
29
-83
2
7
11

Rhythm Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-33
-74
-140
-133
-69
-181
-184
-260
-196
Operating Cash Flow
-29
-62
-122
-121
-146
-173
-136
-113
-115
Investing Cash Flow
-110
-87
-27
158
-62
28
-5
-48
-137
Financing Cash Flow
167
164
163
2
166
213
74
191
217
Change in Cash
27
15
12
38
-41
68
-67
29
-34

Mutual Funds that own Rhythm Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Rhythm Pharmaceuticals.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
7.711671%
5309646
PRIMECAP Odyssey Funds
4.674892%
3218761
Federated Hermes Equity Funds
1.673878%
1152500
SMALLCAP World Fund Inc
1.567997%
1079599
JPMorgan Trust II
1.238251%
852562
See all

Global Institutional Holdings in Rhythm Pharmaceuticals

Funds
Holdings
Peter Kolchinsky
9.68%
Vanguard
8.65%
Felix Baker
8.14%
VANGUARD INDEX FUNDS
7.71%
PRIMECAP Odyssey Funds
4.67%
See all

Rhythm Pharmaceuticals News & Key Events

    Insights on Rhythm Pharmaceuticals

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 6 quarters, 32.70M → 71.25M (in $), with an average increase of 13.8% per quarter

    • imgPOSITIVE IMPACT

      Best in 3 Years

      img

      In the last 3 years, RYTM has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 3 years, RYTM stock has moved up by 315.1%

    • imgPOSITIVE IMPACT

      Profit Spike

      img

      Netprofit is up for the last 2 quarters, -55.63M → -49.29M (in $), with an average increase of 12.9% per quarter

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Moderna, Inc. Common Stock has given 712.1% return, outperforming this stock by 712.6%

    About Rhythm Pharmaceuticals

    Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
    OrganisationRhythm Pharmaceuticals
    Headquarters222 Berkeley Street, Boston, MA, 02116, US
    IndustryBiotechnology
    CEODavid Meeker
    E-voting on sharesClick here to vote

    Key Management of Rhythm Pharmaceuticals

    Name

    Title

    Mr. Joseph Shulman

    Chief Technical Officer

    Mr. David Connolly

    Head of Investor Relations & Corporate Communications

    Mr. Jim Flaherty

    Senior VP & General Counsel

    Ms. Sarah Ryan

    Vice President of Sales & Marketing

    Mr. Hunter C. Smith M.B.A.

    CFO & Treasurer

    Dr. Alastair Garfield Ph.D.

    Chief Scientific Officer

    Mr. Yann Mazabraud

    Executive VP & Head of International

    Ms. Jennifer Lee

    Executive VP & Head of North America

    Mr. Christopher P. German

    Corporate Controller & Principal Accounting Officer

    Dr. David P. Meeker M.D.

    Chairman, President & CEO

    FAQs

    What is Rhythm Pharmaceuticals share price today?

    Rhythm Pharmaceuticals share price today is $98.66 as on at the close of the market. Rhythm Pharmaceuticals share today touched a day high of $99.44 and a low of $96.35.

    What is the 52 week high and 52 week low for Rhythm Pharmaceuticals share?

    Rhythm Pharmaceuticals share touched a 52 week high of $122.20 on and a 52 week low of $74.50 on . Rhythm Pharmaceuticals stock price today i.e. is closed at $98.66,which is 19.26% down from its 52 week high and 32.43% up from its 52 week low.

    What is Rhythm Pharmaceuticals's market capitalisation today?

    Rhythm Pharmaceuticals market capitalisation is $0.01T as on .

    How to invest in Rhythm Pharmaceuticals Stock (RYTM) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Rhythm Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Rhythm Pharmaceuticals Shares that will get you 0.0152 shares as per Rhythm Pharmaceuticals share price of $98.66 per share as on September 26, 2026 at 8:46 am IST.

    What is the minimum amount required to buy Rhythm Pharmaceuticals Stock (RYTM) from India?

    Indian investors can start investing in Rhythm Pharmaceuticals (RYTM) shares with as little as ₹95.8125 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹958.13 in Rhythm Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Rhythm Pharmaceuticals share’s latest price of $98.66 as on September 26, 2026 at 8:46 am IST, you will get 0.1014 shares of Rhythm Pharmaceuticals. Learn more about fractional shares .

    What are the returns that Rhythm Pharmaceuticals has given to Indian investors in the last 5 years?

    Rhythm Pharmaceuticals stock has given 659.51% share price returns and 29.49% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?